
Name
Skyrizi
No market stories in the last 7 days. The latest coverage is below.
- 7-day mood
- —Not enough data
- Stories, 7 days
- 0
- Last 24 hours
- 0no baseline yet
- Sources
- 3in the latest 4

Mood and coverage · last 7 days
Market chart- Skyrizi · 6-hour average
- Hourly reading
- Stories per hour
No scored stories in the last 7 days.
View as table
| Day | Mood | Stories |
|---|---|---|
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
| Sat, Oct 3 | — | 0 |
| Fri, Oct 2 | — | 0 |
Latest on Skyrizi
Newest first
Healthcare
Expanding RINVOQ And SKYRIZI Uses Might Change The Case For Investing In AbbVie (ABBV)
In late June 2026, AbbVie reported multiple product wins, including new pediatric approvals for SKYRIZI, positive CHMP opinions for RINVOQ in alopecia areata a…
Healthcare
How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results?
ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.
Healthcare
AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
AbbVie (NYSE:ABBV) presented new long term clinical and real world data for its gastroenterology portfolio at the 2026 Digestive Disease Week. The data highlig…

